COMP <GO>
EXEL vs LLY // FREE CASH FLOW YIELD
Exelixis Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: EXEL 9
— LLY 5
▲ FREE CASH FLOW YIELD LEADER: EXEL
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
fcf-yield
5.34%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
fcf-yield
2.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.64% | +12.36 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 32.36% | +2.74 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 36.4x | -18.02 | EXEL | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 5.34% | 2.30% | +3.04 | EXEL | /fcf-yield <GO> |
| Operating Margin | 37.60% | 40.21% | -2.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 31.90% | +1.80 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 45.51% | -38.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 9.29 | +7.35 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.7 | 77.9 | +3.77 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.51 | +0.45 | EXEL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 26.3x | -6.75 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | LLY REV | EXEL GROSS % | LLY GROSS % | EXEL FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $65.18B | 96.4% | 83.0% | $875.8M | $16.81B |
| FY 2024 | $2.17B | $45.04B | 96.5% | 81.3% | $671.5M | $8.82B |
| FY 2023 | $1.83B | $34.12B | 44.0% | 79.3% | $251.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
LLY // BETA 0.51